Seres Therapeutics (NASDAQ:MCRB) Lowered to “Sell” Rating by StockNews.com

StockNews.com lowered shares of Seres Therapeutics (NASDAQ:MCRB) from a hold rating to a sell rating in a research note released on Wednesday.

MCRB has been the topic of a number of other research reports. Chardan Capital reiterated a “buy” rating and issued a $1.25 price objective on shares of Seres Therapeutics in a report on Wednesday, November 13th. Canaccord Genuity Group reiterated a “buy” rating and issued a $10.00 price objective on shares of Seres Therapeutics in a report on Thursday, November 14th. Finally, JPMorgan Chase & Co. downgraded Seres Therapeutics from a “neutral” rating to an “underweight” rating in a report on Thursday, October 24th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, Seres Therapeutics has a consensus rating of “Hold” and an average target price of $5.08.

Seres Therapeutics Price Performance

MCRB stock opened at $0.92 on Wednesday. Seres Therapeutics has a 1 year low of $0.54 and a 1 year high of $2.05. The firm has a market capitalization of $156.23 million, a P/E ratio of -3.81 and a beta of 2.06. The business’s 50-day moving average is $0.81 and its two-hundred day moving average is $0.90.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in Seres Therapeutics by 12.1% during the 1st quarter. Vanguard Group Inc. now owns 6,734,821 shares of the biotechnology company’s stock worth $5,213,000 after buying an additional 729,514 shares during the last quarter. Virtu Financial LLC purchased a new position in Seres Therapeutics during the 1st quarter worth approximately $73,000. Point72 DIFC Ltd purchased a new position in Seres Therapeutics during the 2nd quarter worth approximately $64,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in Seres Therapeutics during the 2nd quarter worth approximately $92,000. Finally, Providence Wealth Advisors LLC grew its stake in Seres Therapeutics by 49.5% during the 2nd quarter. Providence Wealth Advisors LLC now owns 76,250 shares of the biotechnology company’s stock worth $58,000 after buying an additional 25,250 shares during the last quarter. Hedge funds and other institutional investors own 59.34% of the company’s stock.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.